Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPeach State Health Plan Pegasys Coverage & Prior A…
    Ask Trek AI about this page
    CurrentPeach State Health PlanPolicy CP.PHAR.89

    Peginterferon alfa-2a (Pegasys) Coverage Criteria

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy CP.PHAR.89 alerts

    Get alerted when Policy CP.PHAR.89 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage criteria, and authorization rules for peginterferon alfa-2a (Pegasys) across commercial, HIM/ICHRA, and Medicaid lines of business for Peach State Health Plan.

    Policy Summary
    PayerPeach State Health Plan
    PolicyPeginterferon alfa-2a (Pegasys) Coverage Criteria
    Policy CodePolicy CP.PHAR.89
    Change TypeAnnual review — no material changes
    Effective DateAug 26, 2024
    Next Review DateAug 26, 2025
    Key ActionPrior authorization required with documentation that the member meets the specific approval criteria for the requested indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    48 weeksmaximum CHB treatment duration
    180 mcg/weekmaximum weekly dose (adult CHB)
    12 monthsinitial approval duration (Medicaid)
    6 monthsinitial approval duration (Commercial)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not authorized
    coverage for CHC
    J3590, S0145HCPCS codes referenced

    Coverage Criteria

    inv-01: Initial Approval — NCCN-Recommended Off-Label Indications

    Covered when ALL of the following are met

    NCCN off-label criteria: 1. Diagnosis is one of the listed NCCN-recommended off‑label conditions: (a) myeloproliferative neoplasms: i) myelofibrosis, low risk and symptomatic; ii) polycythemia vera; iii) essential thrombocythemia; (b) systemic mastocytosis; (c) hairy cell leukemia when prescribed as a single agent; (d) Erdheim‑Chester disease; (e) primary cutaneous anaplastic large cell lymphoma when prescribed as a single agent; (f) adult T‑cell leukemia/lymphoma when prescribed in combination with zidovudine; (g) mycosis fungoides or Sézary syndrome; (h) chronic myeloid leukemia during pregnancy. 2. Prescribed by or in consultation with an oncologist. 3. For Erdheim‑Chester disease, used as single agent for symptomatic or relapsed/refractory disease. 4. Request meets one of the following: (a) dose does not exceed 3 mcg/kg per week; or (b) dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence). 5. Prescribed regimen must be FDA‑approved or recommended by NCCN.Dose ≤ 3 mcg/kg/week unless supported by guidelines

    Prescriber must submit supporting evidence when dose exceeds 3 mcg/kg/week

    inv-02: Initial Approval — Chronic Hepatitis B (CHB)

    Covered when ALL of the following are met

    CHB criteria: 1. Diagnosis of chronic hepatitis B virus (CHB) infection. 2. Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist. 3. Age ≥ 3 years. 4. ONE of: (a) Two elevated ALT lab values within the past 12 months (≥70 IU/L for men, ≥50 IU/L for women) AND HBV DNA ≥20,000 IU/mL for HBeAg‑positive members or >2,000 IU/mL for HBeAg‑negative members; (b) Age ≥18 with cirrhosis and HBV DNA >2,000 IU/mL; (c) Liver biopsy showing moderate/severe necroinflammation (Grade 9–18) or significant fibrosis (Stage 2–4). 5. If age ≤17 years, member does not have cirrhosis. 6. Total treatment period does not exceed 48 weeks. 7. Dose does not exceed 180 mcg per week.Dose ≤ 180 mcg/week; treatment ≤ 48 weeks

    Prescribed regimen must be FDA‑approved or recommended by NCCN

    inv-03: Continued Therapy — All Indications Except CHC

    Covered when ALL of the following are met

    Continued therapy criteria: 1. Member is currently receiving Pegasys via the benefit, or documentation supports the member has received Pegasys for a covered indication for at least 30 days. 2. Member is responding positively to therapy. 3. For melanoma, total treatment period does not exceed 5 years. 4. For CHB, total treatment period does not exceed 48 weeks. 5. If request is for a dose increase, request meets one of: (a) new dose does not exceed 180 mcg per week; or (b) new dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA‑approved or recommended by NCCN.≥30 days on therapy for continuation; dose ≤180 mcg/week when increasing

    Approval durations vary by line of business (see approval durations)

    inv-04: Chronic Hepatitis B (CHB) Coverage

    Covered when ALL of the following are met for CHB (as described in policy history and dosing):

    CHB initial therapy: 1. Adult dosing: 180 mcg subcutaneous (SC) once weekly as monotherapy for up to 48 weeks. 2. Pediatric dosing: 180 mcg/1.73 m2 × body surface area SC once weekly for up to 48 weeks. 3. Total CHB treatment period does not exceed 48 weeks. 4. Dose does not exceed 180 mcg per week.Treatment duration ≤ 48 weeks; dose ≤ 180 mcg/week

    Clarification added in policy history to align total CHB treatment period with existing approval duration

    inv-05: NCCN-Recommended Off-Label Indications

    NCCN-recommended off-label oncology indications (policy history indicates these exist and were modified over time):

    NCCN off-label oncology indications: Off‑label oncology indications supported by NCCN as listed in the policy (examples include chronic myeloid leukemia during pregnancy; myeloproliferative neoplasms such as myelofibrosis low‑risk symptomatic, polycythemia vera, essential thrombocythemia; systemic mastocytosis; Erdheim‑Chester disease; primary cutaneous anaplastic large cell lymphoma; adult T‑cell leukemia/lymphoma in combination with zidovudine; mycosis fungoides/Sezary syndrome; hairy cell leukemia as single agent). Indication‑specific criteria, age considerations, and monotherapy requirements apply per NCCN and policy history.Varies by indication

    Policy history revisions have added/clarified specific indications and monotherapy requirements; evidence of NCCN support required

    Melanoma continuation: Continued therapy durations for melanoma align with existing approval durations up to 5 years where applicable.≤ 5 years total

    Clarifying continuation durations added in policy history

    The policy lists specific indications that are not authorized. These include treatment of chronic hepatitis C (CHC); uncontrolled autoimmune hepatitis; use following heart, lung, or kidney transplants; members with a prior history of drug or alcohol abuse who have not abstained for at least 3 months before starting therapy; and use solely to reduce risk of hepatocellular carcinoma in members with cirrhosis. Non‑FDA approved indications not addressed in this policy require documentation consistent with applicable off‑label use policies.

    Per the AASLD/IDSA HCV guidance, interferon‑based regimens are no longer recommended for chronic hepatitis C (CHC) as of 2018 because they have been superseded by safe and effective direct‑acting antiviral (DAA) agents. Consequently, approval for PEG‑interferon for CHC is listed as Not applicable in this policy.

    The policy states that interferon‑based regimens are no longer recommended for CHC consistent with the 2018 AASLD‑IDSA guidance; therefore, treatment of CHC with peginterferon is not authorized under this policy. Approval duration for CHC is documented as Not applicable.

    Appendix D explicitly notes that the 2018 AASLD/IDSA Hepatitis C treatment guidelines state PEG‑interferon is not recommended for CHC because it has been superseded by regimens containing direct‑acting antivirals. When DAAs are appropriate, use of peginterferon alfa‑2a would therefore not be supported by this guidance and is not authorized by the policy.

    Initial Therapy Criteria

    inv-27: Initial therapy — Initial approval criteria vary by indication (NCCN off-label, CHB).

    Initial approval criteria vary by indication (NCCN off‑label, CHB).

    Initial CHB: See CHB criteria: diagnosis of CHB; specialist prescriber or consultation; age ≥3 years; lab/biopsy thresholds or cirrhosis criteria; if age ≤17 years, no cirrhosis; total treatment period ≤48 weeks; dose ≤180 mcg/week.Dose ≤180 mcg/week; treatment ≤48 weeks

    Initial approval duration for CHB aligns with approval duration and policy history clarifications

    Initial NCCN off‑label: See NCCN‑recommended off‑label criteria: diagnosis must match listed NCCN indications; prescriber must be or consult with an oncologist; dose ≤3 mcg/kg/week unless supported by guidelines/literature; regimen must be FDA‑approved or NCCN‑recommended.Varies by indication

    Initial approval durations for NCCN off‑label indications were revised by line of business in policy history

    Continuation / Continued Therapy Criteria

    inv-29: Continued therapy — Criteria for continued therapy for covered indications (excluding CHC).

    Criteria for continued therapy for covered indications (excluding CHC).

    Continued therapy general: 1. Member currently receiving Pegasys via the benefit, or documentation supports ≥30 days of therapy for a covered indication. 2. Member demonstrating positive response to therapy. 3. Duration limits apply (melanoma ≤5 years; CHB ≤48 weeks). 4. Dose increases must meet constraints: new dose ≤180 mcg/week or be supported by practice guidelines/peer‑reviewed literature with supporting evidence from prescriber.≥30 days on therapy for continuation; dose ≤180 mcg/week when increasing

    Approval durations differ by line of business; see policy history for clarifications

    inv-30: Continuation Therapy Durations

    Continued therapy clarifications added in 3Q 2026 annual review:

    CHB continuation clarification: Total treatment durations for CHB should align with existing approval durations and must not exceed 48 weeks.

    Coding

    HCPCS Codes referencedHCPCS
    J3590Unclassified biologics
    S0145Injection, pegylated interferon alfa-2a, 180 mcg per mL
    HBV DNA and ALT thresholds for CHB — treatment criteria
    ALT requirementTwo ALT values within the past 12 months ≥70 IU/L (men) or ≥50 IU/L (women)
    HBV DNA requirement (HBeAg-positive)HBV DNA ≥20,000 IU/mL
    HBV DNA requirement (HBeAg-negative)HBV DNA >2,000 IU/mL
    HBV DNA treatment threshold
    Treatment threshold> 2,000 IU/mL
    Context — HBeAg-negative CHBCHB therapy recommended for persons with immune-active CHB and cirrhosis if HBV DNA is > 2,000 IU/mL, regardless of ALT
    Context — HBeAg-positive CHB

    Provider Actions & Requirements

    Prior Authorization

    Obtain prior authorization with supporting clinical evidence

    Prior authorization is required for Pegasys. Submit supporting documentation demonstrating the member meets the specific approval criteria for the requested indication (e.g., NCCN off‑label criteria or CHB lab/biopsy thresholds and specialist consultation).

    Prior Authorization

    Confirm PA approval durations by line of business

    Prior authorization rules and approval durations vary by indication and line of business; review the policy history for specific approval durations (Commercial, Medicaid, HIM/ICHRA) as these have been revised over time.

    • Examples in policy history: non‑Commercial NCCN off‑label initial approvals revised from 6 to 12 months; Commercial non‑CHC approvals revised to 6 months or to member renewal date, whichever is longer.
    • CHB clarifications limit total treatment period to ≤ 48 weeks.

    Step Therapy

    StepRequirement
    1
    Prescriber must be the patient’s oncologist or consult with an oncologist; dose must not exceed 3 mcg/kg per week unless the higher dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).
    StepRequirement
    1
    For chronic hepatitis C (CHC), direct-acting antivirals (DAAs) are preferred per AASLD/IDSA guidance; PEG-interferon is not recommended for CHC and should not be used when DAAs are appropriate.

    Quantity Limits & Product

    Peginterferon alfa-2a — 180 mcg presentations
    Vial presentation180 mcg/mL vial
    Prefilled syringe presentationPrefilled syringe: 180 mcg/0.5 mL (4 syringes/pack)
    Administration routeSC (subcutaneous) per product labeling

    Site of Care

    Note

    Subcutaneous (SC) administration per product labeling; weekly dosing

    Administer subcutaneously per product labeling; dosing for CHB is described as 180 mcg SC once weekly in adults (pediatric dosing per PI).

    • Product presentations: vial 180 mcg/mL and prefilled syringe 180 mcg/0.5 mL.

    Definitions

    CHB — definition and therapy guidance
    DefinitionChronic hepatitis B infection (CHB), subdivided into HBeAg-positive and HBeAg-negative
    Therapy guidanceHBV DNA thresholds guide therapy: HBeAg-positive often >20,000 IU/mL; HBeAg-negative often 2,000–20,000 IU/mL
    Coverage criteria referencePolicy requires specialist consultation and age ≥3 years plus lab/biopsy thresholds for CHB treatment
    ALT upper limit of normal (AASLD)
    AASLD ULN (men)35 IU/L
    AASLD ULN (women)25 IU/L
    Source guidance

    Background

    Peginterferon alfa‑2a (Pegasys) is a pegylated recombinant interferon alfa‑2a indicated in this policy for select viral hepatitis and certain hematologic/oncologic conditions. The policy clarifies that interferon‑based regimens have been superseded for chronic hepatitis C by direct‑acting antivirals per the 2018 AASLD/IDSA guidance, and therefore CHC treatment with Pegasys is not authorized. For other covered uses (for example chronic hepatitis B and selected NCCN‑recommended off‑label oncology indications), the policy requires specialist involvement, defined laboratory or biopsy thresholds, adherence to dosing limits, and prior authorization with supporting documentation.

    Policy Summary
    PayerPeach State Health Plan
    PolicyPeginterferon alfa-2a (Pegasys) Coverage Criteria
    Policy CodePolicy CP.PHAR.89
    Change TypeAnnual review — no material changes
    Effective DateAug 26, 2024
    Next Review DateAug 26, 2025
    Key ActionPrior authorization required with documentation that the member meets the specific approval criteria for the requested indication.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation / Continued Therapy CriteriaCodingProvider Actions & RequirementsStep TherapyQuantity Limits & ProductSite of CareDefinitionsBackground

    inv-28: Initial Therapy / Approval Durations

    Initial approval durations and rules have been updated in policy history by line of business:

    CHB initial approval: Initial approval duration for CHB aligns with existing approval duration and does not exceed 48 weeks.≤ 48 weeks

    3Q 2026 clarification noted in policy history

    NCCN off‑label initial approval: Initial approval durations for NCCN‑Recommended Off‑Label Indications were revised for non‑Commercial lines from 6 months to 12 months. For Commercial line of business, non‑CHC initial approval durations were revised to '6 months or to the member's renewal date, whichever is longer.'Varies by line of business

    See policy history for effective dates and lines of business

    ≤ 48 weeks

    Clarification added in 3Q 2026 to align with approval duration

    Melanoma continuation clarification: Continued therapy durations for melanoma align with existing approval duration of up to 5 years.≤ 5 years

    Clarification added in 3Q 2026

    HBV-DNA levels are typically >20,000 IU/mL in HBeAg-positive CHB
    Pegasys dosing for chronic hepatitis B (CHB)
    Adult dose (CHB)180 mcg subcutaneously (SC) once weekly
    Pediatric dosing notePediatrics: 180 mcg/1.73 m2 x BSA SC weekly for 48 weeks
    Maximum weekly doseDose does not exceed 180 mcg per week
    Step Therapy

    Off‑label oncology: oncologist involvement and dose limits

    For NCCN‑recommended off‑label oncology indications, the prescriber must be the oncologist or consult with one, and dosing must not exceed 3 mcg/kg per week unless supported by practice guidelines or peer‑reviewed literature (prescriber must submit evidence if exceeding).

    • Dose > 3 mcg/kg/week requires supporting evidence in the request.
    Step Therapy

    CHC step consideration — DAAs preferred; PEG‑interferon not recommended

    For chronic hepatitis C (CHC) requests: recognize that AASLD/IDSA guidance no longer recommends PEG‑interferon for CHC because direct‑acting antivirals supersede interferon‑based regimens; this supports exclusion/step pathways favoring DAAs where appropriate.

    • CHC treatment with peginterferon is listed among diagnoses for which coverage is NOT authorized.
    Documentation Required

    Submit required clinical documentation with PA request

    Provider must submit documentation (office chart notes, lab results, or other clinical information) that the member meets all approval criteria when requesting authorization.

    • Include specialist consultation notes when required (oncology for off‑label oncology uses; gastroenterology/hepatology/ID for CHB).
    • Include relevant labs (e.g., two ALT values, HBV DNA) or biopsy reports for CHB criteria.
    Documentation Required

    Follow product labeling and guideline-based supporting documentation

    Prescribing should follow the product labeling and referenced guidelines (Pegasys Prescribing Information and AASLD/IDSA guidance); include citations or PI excerpts when relevant to support dosing or indication decisions.

    • Reference Pegasys PI (Dailymed) and NCCN or AASLD/IDSA guidance in the request when applicable.
    Denial Risk

    Denial risk: CHC and non‑addressed off‑label indications

    Requests to treat chronic hepatitis C (CHC) with Pegasys are not authorized per this policy; non‑listed off‑label uses require adherence to the applicable off‑label use policies and sufficient documentation of efficacy and safety.

    • For non‑FDA indications not addressed by this policy, submit evidence per off‑label use policies CP.CPA.09 (Commercial), HIM.PA.154 (HIM/ICHRA), or CP.PMN.53 (Medicaid).
    Billing Rule

    Coding reminder — verify coding before claim submission

    Inclusion or exclusion of listed codes is informational only and does not guarantee coverage; providers should verify current professional coding guidance prior to claim submission.

    • HCPCS codes referenced in policy: J3590 (Unclassified biologics) and S0145 (Injection, pegylated interferon alfa-2a, 180 mcg per mL).
    AASLD defines upper limit of normal for serum ALT concentrations as 35 IU/L (men) and 25 IU/L (women)
    Significant fibrosis — staging definition
    Significant fibrosis definition (pre-2024)Previously defined as stage 3-4
    Significant fibrosis definition (2024 WHO update)Updated to include stage 2-4
    Policy notePolicy history documents revision of significant fibrosis from stage 3-4 to stage 2-4 per 2024 WHO CHB guidelines
    AASLD ALT upper limit of normal
    AASLD ALT upper limit (men)35 IU/L
    AASLD ALT upper limit (women)25 IU/L
    Guideline sourceValues per AASLD 2018 guidance referenced in policy appendix